Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses

Ewa Cendrowicz, PhD, Lisa Jacob, Shirley Greenwald, Ami Tamir, Yosi Gozlan, Gerwin Huls, MD PhD, Adam Foley-Comer, Yaron Pereg, Ayelet Chajut, Amnon Peled, PhD, Edwin Bremer, PhD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140280

Published: 2020

Journal Articles

Nicotinamide (NAM) Modulates Transcriptional Signature of Ex Vivo Cultured UCB CD34+ Cells (Omidubicel) and Preserves Their Stemness and Engraftment Potential

Tracey Lodie, PhD, Julian Adams, PhD, Dima Yackoubov, Msc, Yair Steinhardt, MSc, Dorit Ashengrau, Adi Bitansky, Alina Maliutina, Sherry Cohen, Boaz Buhenvald, PhD, Moshe Shahor, PhD, Nathan Dinowitz, PhD, Vered Caspi, PhD, Amnon Peled, PhD, Tony Peled, MSc

Blood (2019) 134 (Supplement_1): 3718.

https://doi.org/10.1182/blood-2019-131124

Published: 2019

Journal Articles

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

Jun Xia, PhD, Stephanie Sun, Matthew RM Jotte, Geoffrey L. Uy, MD, Osnat Bohana-Kashtan, PhD, Ella Sorani, PhD, Abi Vainstein, Amnon Peled, PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2745.

https://doi.org/10.1182/blood-2019-128881

Published: 2019

Journal Articles

The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and Their Terminal Differentiation By Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression

Michal Abraham, PhD, Shiri Klein, Baruch Bulvik, Hanna Wald, Dvora Holam, Lola Weiss, Katia Beider, PhD, Orly Eizenberg, Ori Wald, MD PhD, Abraham Avigdor, MD, Ohad Benjamini, MD, Eithan Galun, MD, Arnon Nagler, Yaron Pereg, PhD, Amnon Peled, PhD

Blood (2016) 128 (22): 767.

https://doi.org/10.1182/blood.V128.22.767.767

Published: 2016

Journal Articles

The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to HDAC Inhibitor Panobinostat through Inhibition of p21 and Mitosis Regulators, Sensitizing MM Cells to DNA-Damaged Induced Apoptosis

Katia Beider, PhD, Valeria Voevoda, Hanna Bitner, Evgenia Rosenberg, Hila Magen, MD, Olga Ostrovsky, PhD, Merav Leiba, MD, Noya Shilo, MD, Avichai Shimoni, MD, Michael Milyavsky, PhD, Amnon Peled, PhD, Arnon Nagler

Blood (2016) 128 (22): 891.

https://doi.org/10.1182/blood.V128.22.891.891

Published: 2016

Journal Articles

The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia

Blood (2016) 128 (22): 2745.

https://doi.org/10.1182/blood.V128.22.2745.2745

Published: 2016

Journal Articles

The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia

Blood (2015) 126 (23): 2546.

https://doi.org/10.1182/blood.V126.23.2546.2546

Published: 2015

Journal Articles

BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial

Gautam Borthakur, MD, Arnon Nagler, MD, Yishai Ofran, MD, Jacob M. Rowe, MD, Jessica K. Altman, MD, Olga Frankfurt, MD, Martin S. Tallman, MD, Irit Avivi, Amnon Peled, PhD, Yaron Pereg, PhD, Adam Foley-Comer, MD, Lena Russovsky, BS, Arnon Aharon, MD, Teresa McQueen, BS, Naveen Pemmaraju, MD, Carlos E. Bueso-Ramos, MD PhD, Jorge E. Cortes, MD, Michael Andreeff, MD PhD

Blood (2014) 124 (21): 950.

https://doi.org/10.1182/blood.V124.21.950.950

Published: 2014

Journal Articles

S1P Modulator FTY720 Targets Multiple Myeloma Cell Proliferation and Stromal Interactions Via CXCR4/CXCL12 and mTOR Pathways

Katia Beider, PhD, Evgenia Rosenberg, Hanna Bitner, Merav Leiba, MD, Maya Koren-Michowitz, MD, Michal Abraham, PhD, Shiri Klein, Hanna Wald, Avichai Shimoni, MD, Amnon Peled, PhD, Arnon Nagler, MD

Blood (2014) 124 (21): 4707.

https://doi.org/10.1182/blood.V124.21.4707.4707

Published: 2014

Journal Articles

CXCR4 Promotes the Tumorogenicity of Multiple Myeloma, Including Increased Motility, Clonogenicity, up-Regulation of VLA-4, Protection From Chemotherapy and Aggressive Tumor Development In Vivo

Katia Beider, Amnon Peled, PhD, Lola Weiss, Merav Leiba, Avichai Shimoni, MD, Arnon Nagler

Blood (2011) 118 (21): 1801.

https://doi.org/10.1182/blood.V118.21.1801.1801

Published: 2011

Journal Articles

Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors

Mariela Sivina, PhD, Robert J. Kreitman, MD, Amnon Peled, PhD, Farhad Ravandi, MD, Jan A. Burger, MD, PhD

Blood (2011) 118 (21): 1760.

https://doi.org/10.1182/blood.V118.21.1760.1760

Published: 2011

Journal Articles

Nicotinamide, a Form of Vitamin B 3 , Promotes Expansion of Natural Killer Cells That Display Increased In Vivo Survival and Cytotoxic Activity,

Gabi M Frei, Nurit Persi, Chana Lador, Amnon Peled, PhD, Yael C Cohen, Arnon Nagler, Tony Peled

Blood (2011) 118 (21): 4035.

https://doi.org/10.1182/blood.V118.21.4035.4035

Published: 2011

Journal Articles

CXCR4 Antagonist BKT140 Synergizes with Rituximab, Targeting Non Hodgkin Lymphoma (NHL) In Vitro and In Vivo in a Xenograft Model with Bone Marrow Involvement

Katia Beider, Elena Ribakovsky, Michal Abraham, Hanna Wald, Orly Eizenberg, Abraham Avigdor, MD, Amnon Peled, PhD, Arnon Nagler

Blood (2011) 118 (21): 952.

https://doi.org/10.1182/blood.V118.21.952.952

Published: 2011

NARROW

DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses

Nicotinamide (NAM) Modulates Transcriptional Signature of Ex Vivo Cultured UCB CD34+ Cells (Omidubicel) and Preserves Their Stemness and Engraftment Potential

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and Their Terminal Differentiation By Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression

The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to HDAC Inhibitor Panobinostat through Inhibition of p21 and Mitosis Regulators, Sensitizing MM Cells to DNA-Damaged Induced Apoptosis

The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia

The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia

BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial

S1P Modulator FTY720 Targets Multiple Myeloma Cell Proliferation and Stromal Interactions Via CXCR4/CXCL12 and mTOR Pathways

CXCR4 Promotes the Tumorogenicity of Multiple Myeloma, Including Increased Motility, Clonogenicity, up-Regulation of VLA-4, Protection From Chemotherapy and Aggressive Tumor Development In Vivo

Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors

Nicotinamide, a Form of Vitamin B 3 , Promotes Expansion of Natural Killer Cells That Display Increased In Vivo Survival and Cytotoxic Activity,

CXCR4 Antagonist BKT140 Synergizes with Rituximab, Targeting Non Hodgkin Lymphoma (NHL) In Vitro and In Vivo in a Xenograft Model with Bone Marrow Involvement

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only